Company Information

    Genomenon was founded on January 2014. The company is based in Ann Arbor, MI, USA . The number of employees in Genomenon is less than 50. Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making.

    Here is how Genomenon describes itself: "The world’s most comprehensive source of genomic evidence. We help you identify critical biomarkers for NGS. Download Mastermind today!"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Genomenon has received 6 rounds of venture funding. The total funding amount is around $11.1M. Last venture funding round was $5.3M, announced on March, 2021.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Genomenon - Blog

                          • Don’t Miss Variants: Upgrading From the Cited Variants Reference to the Mastermind API

                          • In this blog, chief technology officer Steve Schwartz describes the limitations of the Mastermind Cited Variants Reference (CVR) that affect genomic analyses, and how the integration of Mastermind’s API can help surmount them. The Mastermind Cited Variants Reference (CVR) is an open-access file, available in VCF (variant call format) or CSV (comma-separated values) formats for … Continue readingThe post Don’t Miss Variants: Upgrading From the Cited Variants Reference to the Mastermind API appeared first on Genomenon.
                          • Accelerating Rare Disease Diagnosis with Genomic Data

                          • Genomenon CEO, Mike Klein, shares how Mastermind’s new Disease-Specific Curated Content is helping clinicians discover new treatment options for rare diseases. Disease-Specific Curated Content Shortens the Diagnostic Odyssey Genomenon has developed a new feature in the Mastermind Genomic Search Engine that enables faster and more accurate diagnosis of rare diseases. Disease-Specific Curated Content gives clinical … Continue readingThe post Accelerating Rare Disease Diagnosis with Genomic Data appeared first on Genomenon.
                          • OUR RARE STORIES | Rare Disease Day 2022

                          • In honor of Rare Disease Day February 28, 2022, we are excited to present Genomenon’s “Our Rare Stories” Live Blog, where we will be compiling articles, informative webinars, press releases, and other compelling resources that all play a part in highlighting the inspiration for our mission—patient stories. Monday, FEBRUARY 28, 2022 “Our Rare Stories” has … Continue readingThe post OUR RARE STORIES | Rare Disease Day 2022 appeared first on Genomenon.
                          • Guest Blog: Don’t Forget Morgan – Elle’s Story

                          • In June of 2016, I sat with my husband in a doctor’s office awaiting the results of genetic testing that had been performed on our daughter, Elle. Elle was five at the time and had struggled with global developmental delay, particularly speech and language development, since birth. When she had begun to experience atypical seizures, … Continue readingThe post Guest Blog: Don’t Forget Morgan – Elle’s Story appeared first on Genomenon.
                          • Rapid Variant Interpretation with the Mastermind Relevancy Score

                          • The key to rapid and accurate literature curation for clinical interpretation and therapeutic discovery is standardizing and optimizing the review process. The Mastermind Genomic Search Engine meets this need with a collection of sophisticated algorithms that prioritize search results by relevance. This proprietary process is called the Mastermind Relevancy Score. Why is the Mastermind Relevancy … Continue readingThe post Rapid Variant Interpretation with the Mastermind Relevancy Score appeared first on Genomenon.
                          • Top Three Benefits of Locus-Specific Patient Databases for Rare Disease

                          • In a recent webinar, Genomenon’s chief scientific officer Dr. Mark Kiel was joined by Dr. Gus Khursigara, VP of Medical Affairs and Clinical Strategy at Inozyme Pharma. This blog explores three key benefits of locus-specific patient databases (or Patient Landscapes), and how they are helping Inozyme better understand and target rare diseases. 1. Patient Landscapes … Continue readingThe post Top Three Benefits of Locus-Specific Patient Databases for Rare Disease appeared first on Genomenon.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *